Trial Profile

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 31 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pabinafusp alfa (Primary) ; Pabinafusp alfa (Primary) ; Idursulfase
Indications Mucopolysaccharidosis II
Focus Registrational; Therapeutic Use
Acronyms Starlight
Sponsors JCR Pharmaceuticals

Most Recent Events

27 Jan 2026 According to JCR Pharmaceuticals media release, data from the trial will be presented at the 22nd Annual WORLDSymposium™ 2026, held February 2-6, 2026, in San Diego, Calif.
02 Jul 2025 According to a JCR Pharmaceuticals media release, the company achieved the enrollment of the target number of participants in this trial
02 Jul 2025 Status changed from recruiting to active, no longer recruiting, as per JCR Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com